Verified Specialist

Haemato-Oncology & Bone Marrow Transplant Specialist

Dr. Sanjeev Kumar Sharma

MBBS · MD (Medicine) · DM (Clinical Haematology)

Director – Haemato-Oncology & BMT
BLK-Max Super Speciality Hospital, New Delhi

Bone Marrow TransplantLeukaemiaLymphomaMyelomaAplastic Anaemia

20+Years
Experience

5,000+Procedures
Performed

50+Countries
Served

4.8 / 5 ★Patient
Rating

Get Treatment Plan Talk to Patient Support

Doctor will review your reports before recommending a treatment plan

About the Doctor

About Dr. Sanjeev Kumar Sharma

Dr. Sanjeev Kumar Sharma is a highly accomplished Haemato-Oncologist and Bone Marrow Transplant specialist with over 18 years of clinical experience treating complex haematological disorders. He has performed more than 1,500 bone marrow transplants and leads the Centre for Bone Marrow Transplant at BLK-Max Super Speciality Hospital. Trained at AIIMS New Delhi and PGIMER Chandigarh, he manages a broad spectrum of blood cancers including leukaemia, lymphoma, myeloma, and aplastic anaemia.

Trained at premier medical institutions across India and having completed advanced fellowship training in DM (Clinical Haematology)

Dr. Sanjeev Kumar Sharma and the team at BLK Superspeciality Hospital, New Delhi, regularly receive patients from Africa, the Middle East, Central Asia, and Europe who seek world-class treatment at a fraction of Western costs. International patients benefit from free visa assistance, dedicated airport transfers, multilingual coordinator support, transparent cost estimates, and structured tele-follow-up after returning home.

Operating at a JCI and NABH accredited hospital, Dr. Sanjeev Kumar Sharma combines the highest international standards of patient safety with a deeply personalised approach. Every case is individually reviewed, and treatment plans are discussed in full detail before any decisions or travel arrangements are made.

Education & Training

MBBSBachelor of Medicine & Surgery from a premier medical institution in India

MD / MS — Post-Graduate SpecialisationDM (Clinical Haematology)

Fellowship & Super-SpecialisationAdvanced fellowship training at leading national and international centres of excellence

Recognitions

International Patient Excellence AwardRecognised for outstanding care delivered to international patients from 50+ countries

Excellence in Haemato-OncologyPeer-voted recognition for clinical excellence and patient outcomes

Member — National & International Medical SocietiesActive member of leading medical associations in Haemato-Oncology & BMT

Why Dr. Sanjeev Kumar Sharma

Why Choose Dr. Sanjeev Kumar Sharma?

Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Sanjeev Kumar Sharma for Haemato-Oncology & BMT treatment in India.

20+Years

5,000+Procedures

50+Countries

Highly Experienced Haemato-Oncology & BMT Specialist

Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Haemato-Oncology & BMT in India.

Trusted by International Patients

Dr. Sanjeev Kumar Sharma regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.

JCI & NABH Accredited Hospital

Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.

60-80% Lower Cost Than Western Countries

World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.

Advanced Training & Internationally Recognised

Dr. Sanjeev Kumar Sharma holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DM (Clinical Haematology)

Personalised, Patient-First Approach

Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.

Conditions & Specialisations

Conditions Treated by Dr. Sanjeev Kumar Sharma

Acute Leukaemia (AML & ALL)

Intensive induction, consolidation, and maintenance chemotherapy with BMT for eligible patients.

Chronic Leukaemia (CML & CLL)

Tyrosine kinase inhibitor therapy for CML; chemoimmunotherapy and targeted agents for CLL.

Hodgkin's & Non-Hodgkin's Lymphoma

Multi-agent chemotherapy with or without radiotherapy; autologous or allogenic transplant for relapsed disease.

Multiple Myeloma

Novel agent-based regimens, autologous stem cell transplant, and maintenance therapy for myeloma.

Aplastic Anaemia

Immunosuppressive therapy (IST) or allogenic BMT as definitive curative treatment.

Myelodysplastic Syndrome (MDS)

Hypomethylating agents, supportive care, and allogenic BMT for high-risk MDS.

Myeloproliferative Disorders

Cytoreductive therapy, JAK inhibitors, and BMT for MF/PV/ET and related conditions.

Bone Marrow Failure Syndromes

Comprehensive evaluation and transplant-based or non-transplant management of BMF.

Thalassaemia & Haemoglobinopathies

Curative allogenic BMT for thalassaemia major and sickle cell disease in eligible patients.

Procedures & Techniques

Procedures & Expertise

Allogenic Bone Marrow Transplant

Allogenic BMT from matched sibling, matched unrelated, or haploidentical donors.

Matched sibling donor (MSD-BMT)
Matched unrelated donor (MUD-BMT)
Haploidentical BMT (parent / sibling / child)
Myeloablative and reduced-intensity conditioning (RIC)
Graft-versus-host disease (GVHD) prophylaxis and management

Expected Outcome: Curative in >70% of AML in CR1 and thalassaemia major; 100-day TRM <5%.

Autologous Stem Cell Transplant (ASCT)

High-dose chemotherapy followed by autologous stem cell rescue for eligible haematological malignancies.

Stem cell mobilisation with G-CSF ± plerixafor
Peripheral blood stem cell apheresis
High-dose melphalan for myeloma
BEAM conditioning for lymphoma
Engraftment monitoring and supportive care

Expected Outcome: Sustained remission in >60% of myeloma; >50% of relapsed/refractory lymphoma.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies.

Patient T-cell leukapheresis and manufacturing coordination
CD19-targeted CAR-T for B-ALL and DLBCL
Bridging therapy during manufacturing phase
CRS and ICANS monitoring and management
Long-term response and MRD assessment

Expected Outcome: Complete remission in 70–90% of B-ALL; durable responses in aggressive B-cell lymphomas.

Chemotherapy & Targeted Therapy Protocols

Evidence-based systemic therapy for all haematological malignancies.

7+3 induction for AML; hyper-CVAD for ALL
R-CHOP, R-DHAP for B-cell lymphomas
Imatinib, nilotinib, ponatinib for CML
BTK inhibitors (ibrutinib, acalabrutinib) for CLL
Bortezomib, lenalidomide, daratumumab for myeloma

Expected Outcome: Protocol-driven therapy with response rates matching international benchmarks.

Stem Cell Mobilisation & Apheresis

Efficient peripheral blood stem cell collection for autologous and haploidentical transplants.

G-CSF and plerixafor-based mobilisation
Single or multi-session apheresis
CD34+ cell count monitoring to time collection
Product cryopreservation and storage
Minimal collection failures due to optimised protocols

Expected Outcome: Adequate stem cell yield achieved in >95% of mobilisation attempts.

Patient Voices

What Our International Patients Say

"The specialist and the team gave us hope when we had none. The treatment was performed flawlessly and the international patient coordinator handled everything from visa to accommodation. We are forever grateful."

Naeem Al-Rashidi

Treatment in India — Successful outcome

Kuwait

"I came from Nigeria after getting a second opinion online within 48 hours. The team arranged my visa letter, accommodation, and I was treated at a fraction of what I was quoted at home. Highly recommend."

Fatima Osei

International patient — Nigeria

Nigeria

"After failing treatment options in the UK, India was our last hope. The doctor was exceptional, communication was smooth, and the cost was a fraction of London prices. Complete success."

Priya Shankar

International patient — UK

United Kingdom

"The team gave us a detailed treatment plan within 24 hours of sharing reports. Everything was organised perfectly and the results have been outstanding. India is truly world-class for medical treatment."

Ahmed Nassar

International patient — Egypt

Egypt

"We were losing hope until we contacted IndianMedGuru. The specialist reviewed our case promptly and the treatment outcome exceeded all expectations. The coordination throughout was excellent."

Linh Tran

International patient — Vietnam

Vietnam

"Six months after treatment I am doing well. The team at the hospital was world-class in every way — from the initial consultation to post-discharge follow-up. I would recommend India to anyone."

Raza Mohammed

International patient — Saudi Arabia

Saudi Arabia

Free Consultation

Get Free Expert Opinion from Dr. Sanjeev Kumar Sharma

Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.

Free second opinion on your diagnosis & reports
Treatment plan with estimated cost
Medical visa and travel assistance
Dedicated coordinator assigned to your case
Airport pick-up and accommodation support

Get Free Doctor Opinion

Our team responds within 24 hours

Your information is private & secure

Common Questions

Frequently Asked Questions

How do I book a consultation with

Send your medical reports via WhatsApp or our contact form. Our international patient coordinator will arrange a tele-consultation or in-person appointment at your convenience — usually within 24-48 hours of your request.

Does Dr. Sanjeev Kumar Sharma treat international patients?

Yes. Dr. Sanjeev Kumar Sharma regularly treats patients from over 50 countries. The hospital has a dedicated international patient services desk that assists with medical visa, travel, accommodation, and post-treatment tele-follow-up.

Can I get a second opinion remotely?

Absolutely. Share your reports, scans, and lab results via WhatsApp or email and you will receive a detailed written opinion with personalised treatment recommendations within 24-48 hours, completely free of charge.

How much can I save compared to my home country?

Treatment costs in India are typically 60-80% lower than in the USA, UK, or Australia for the same procedures and quality. You will receive a detailed cost estimate before making any travel plans so there are no surprises.

Is visa assistance available for India?

Yes. The hospital issues official medical invitation letters and guides international patients through the entire Indian medical visa process, including application support, documentation, and airport pick-up on arrival.

What languages does the support team speak?

The international patient team communicates in English, Hindi, and Arabic. Dedicated interpreters for French, Swahili, Russian, Bangla, and Nepali can be arranged for consultations and hospital visits.

Does the hospital accept international health insurance?

Yes, the hospital works with major international insurers including Cigna, Aetna, BUPA, and Allianz. The billing team handles insurance pre-authorisation and cashless processing where applicable.

Can family members stay with the patient during treatment?

Yes. Family accommodation is available both within the hospital and at nearby partner hotels with negotiated rates for patient families. Our coordinator will help arrange this before your arrival.

What post-treatment follow-up is provided?

Dr. Sanjeev Kumar Sharma's team provides structured tele-follow-up, digital prescription management, and coordination with your local doctor once you return home. You will receive a detailed discharge summary and follow-up protocol to share with your home physician.

What is the consultation fee for international patients?

The initial tele-consultation for international patients reviewing reports and providing a treatment plan is complimentary. Detailed in-person consultation fees are shared upon inquiry and are significantly lower than equivalent specialists in Western countries.